Sugi Predict

Sugi Predict / Compounds / SCHEMBL13310702

SCHEMBL13310702

SCHEMBL13310702

O=C(/C=C(O)/C=C/c1ccc(O)c(O)c1)CCc1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.53
▸ CA1 P00915 2/20 0.53
▸ CA4 P22748 2/20 0.53
▸ CA6 P23280 2/20 0.53
▸ CA5A P35218 2/20 0.53
▸ CA7 P43166 2/20 0.53
▸ CA9 Q16790 2/20 0.53
▸ CA14 Q9ULX7 2/20 0.53
▸ CA5B Q9Y2D0 2/20 0.53
▸ IAPP P10997 3/20 0.52
▸ MMP1 P03956 3/20 0.52
▸ MMP2 P08253 3/20 0.52
▸ MMP9 P14780 3/20 0.52
▸ APP P05067 5/20 0.51
▸ HSD17B10 Q99714 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ CYP3A4 P08684 3/20 0.51
▸ ALOX5 P09917 3/20 0.51
▸ MAPK1 P28482 3/20 0.51
▸ AKR1B10 O60218 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13310700 0.89 GSK3B (0.58) CA12CA1CA4CA6CA5A
SCHEMBL14401548 0.87 IAPP (0.53) CA12CA1CA4CA6CA5A
SCHEMBL29565226 0.86 HTR1A (0.69) CA12CA1CA4CA6CA5A
SCHEMBL14629577 0.83 TRPV1 (0.52) CA12CA1CA4CA6CA5A
SCHEMBL30449722 0.82 ALOX5 (0.67) CA12CA1CA4CA6CA5A
SCHEMBL4545217 0.82 ALOX5 (0.67) CA12CA1CA4CA6CA5A
SCHEMBL9683152 0.82 IAPP (0.67) CA12CA1CA4CA6CA5A
SCHEMBL8848008 0.82 IAPP (0.67) CA12CA1CA4CA6CA5A
SCHEMBL1976133 0.81 IAPP (0.66) CA12CA1CA4CA6CA5A
SCHEMBL1976131 0.81 IAPP (0.66) CA12CA1CA4CA6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728043-B2 Methods for treatment of beta-amyloid protein-induced ocular disease KIM DARRICK S H L 2010-06-01 — — US disclosed
US-7572829-B2 Pharmaceutical compositions useful in prevention and treatment of Beta-amyloid protein-induced disease KIM DARRICK S H L 2009-08-11 — — US disclosed
US-20080085932-A1 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease KIM DARRICK S 2008-04-10 — — US disclosed
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease KIM DARRICK S H 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070003641-A1 Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease APP, BACE1, GSAP CA12 2512/4885CA1 959/4885CA4 3543/4885
US-20080085932-A1 Pharmaceutical Compositions Useful In Prevention and Treatment of Beta-Amyloid Protein-Induced Disease APP, BACE1, PSEN1 CA12 1292/4885CA1 559/4885CA4 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.